Oral Prostacyclins/Analogs for PAH: Current Status and Challenges

Rubin, Lewis
June 2012
Current Medical Literature: Pulmonary Hypertension;2012 Supplement, p7
Academic Journal
The article discusses the current status and challenges of prostacyclin therapy to pulmonary hypertension (PH) patients. It claims that different studies have been conducted whose goal is to explore the effectiveness of three main prostanoids including treprostinil, beraprost and selexipag. It indicates that patients with PH have been treated with prostanoids intravenously and subcutaneously. However, it notes that effective dosing and pharmacokinetics are yet to be further studied in the future.


Related Articles

  • Prostacyclins in Pulmonary Hypertension: The Need for Earlier Therapy. Vachiéry, Jean-Luc // Current Medical Literature: Pulmonary Hypertension;2012 Supplement, p8 

    The article examines clinical trials of prostacyclins in patients with pulmonary arterial hypertension (PAH). It mentions a diagnostic algorithm from the European Society of Cardiology and the European Respiratory Society which suggests the effectiveness of prostacyclin therapies for PAH...

  • BROMELAIN: AN ANTI-INFLAMMATORY AGENT. Seligman, Bert // Angiology;Nov1962, Vol. 13 Issue 11, p508 

    Discusses the pharmacological characteristics of bromelain. Functions of bromelain; Arterial diseases that can be manage with bromelain; Indications of bromelain.

  • Role of prostacyclin in pulmonary hypertension. Mitchell, Jane A.; Ahmetaj-Shala, Blerina; Kirkby, Nicholas S.; Wright, William R.; Mackenzie, Louise S.; Reed, Daniel M.; Mohamed, Nura // Global Cardiology Science & Practice;2014, Vol. 2014 Issue 4, p214 

    Prostacyclin is a powerful cardioprotective hormone released by the endothelium of all blood vessels. Prostacyclin exists in equilibrium with other vasoactive hormones and a disturbance in the balance of these factors leads to cardiovascular disease including pulmonary arterial hypertension....

  • ‘Hedged’ Prescribing for Partially Compliant Patients. Urquhart, John; Vrijens, Bernard // Clinical Pharmacokinetics;2006, Vol. 45 Issue 1, p105 

    The article focuses on the views of the author on several ways which can be used for counterbalancing omitted doses. The authors suggest these ways should be referred to as hedging. In cases of delayed or omitted doses, which is known as partial compliance, substantially higher doses should be...

  • Pulmonary Vascular Versus Right Ventricular Function Changes During Targeted Therapies of Pulmonary Hypertension. Vonk-Noordegraaf, Anton // Current Medical Literature: Pulmonary Hypertension;2012 Supplement, p20 

    The article focuses on a study which looks into the relationship between pulmonary vascular resistance (PVR) and right ventricular ejection fraction (RVEF) in patients with pulmonary hypertension (PH). The study has discovered changes in the right ventricular function and hypertensive pulmonary...

  • Current Management of Primary Pulmonary Hypertension. de Backer, T.L.M.; Smedema, J-P.; Carlier, S.G. // BioDrugs;2001, Vol. 15 Issue 12, p801 

    Primary pulmonary hypertension (PPH) is a rare disorder of the lung vasculature characterised by an increase in pulmonary artery pressure. Although the aetiology of this disease remains unknown, knowledge of the pathophysiology of the disease has advanced considerably. Diagnosis of PPH is...

  • Developing treatments for pulmonary arterial hypertension. Wilkins, Martin R. // Pulmonary Circulation;Jan-Mar2013, Vol. 3 Issue 1, p156 

    Developing new treatments for pulmonary arterial hypertension (PAH) is a challenge. We have enjoyed success with regulatory approvals for three drug classes-prostanoids, endothelin receptor antagonists and phosphodiesterase type 5 inhibitors. But we have also seen some disappointing results, for...

  • Effect of Sepimostat Mesilate on the Development of Glomerulonephritis in NZB/W F1 Mice. Watanabe, Hiroshi; Sato, Shuzo; Saito, Rie; Iwadate, Haruyo; Kobayashi, Hiroko; and Hiromasa Ohira // Open Immunology Journal;2011, Vol. 4, p11 

    Objective: To determine whether sepimostat mesilate inhibits activation of the complement pathways, and to evaluate the effectiveness of sepimostat mesilate on the development of glomerulonephritis in NZB/W F1 mice. Methods: We used the Wielisa complement functional kit to assess the inhibitory...

  • Prostacyclins to Treat PAH in Children and Neonates. Lévy, Marilyne // Current Medical Literature: Pulmonary Hypertension;2011 Supplement, p8 

    In this article the author describes a registry of pediatric patients with pulmonary arterial hypertension (PAH) in Paris, France and discusses the role of treprostinil in the treatment of PAH. The author asserts that the French registry discovers that the main cause of PAH is congenital heart...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics